Yale University

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

TitlePopulation pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Publication TypeJournal Article
Year of Publication2005
AuthorsSmith, Patrick F., Robert Dicenzo, Alan Forrest, Mark Shelton, Gerald Friedland, Michael Para, Richard Pollard, Margaret Fischl, Robin DiFrancesco, and Gene D. Morse
JournalClinical pharmacokinetics
Volume44
Issue1
Pagination99-109
Date Published2005
ISSN0312-5963
KeywordsAdolescent, Adult, Anti-HIV Agents, Body Weight, Carbamazepine, Continental Population Groups, Delavirdine, Double-Blind Method, Drug Therapy, Combination, Female, HIV Infections, Humans, Male, Metabolic Clearance Rate, Middle Aged, Sex Factors
AbstractDelavirdine is a non-nucleoside reverse transcriptase inhibitor used in combination regimens for the treatment of HIV-1 infection. Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies.
DOI10.3109/00952990.2011.568081
Alternate JournalClin Pharmacokinet

External Links